Dihexa is an experimental peptide thought to spur new brain-cell connections. In animals it reliably restored memory at low oral doses, but no human trial exists — so no proven dose, safety record, or benefit in healthy people. It stimulates a growth system that tumors exploit, and is sold only through unregulated suppliers. (Full Review)

Protocol

Dose

No established human dose

Preclinical rodent efficacy at roughly 1–2 mg/kg

Route

Oral

Also sold as solution or transdermal cream; delivered dose uncertain

Schedule

Not established

Anecdotal once-daily use; no evidence supports any schedule

Time to effect

Cognitive effect

Not established in humans

Rodent improvements measured over days of dosing

Benefits

Low: Memory restoration in animal models of cognitive impairment; synaptogenesis and neuroplasticity

Speculative: Cognitive enhancement in healthy individuals; neuroregeneration after nerve or brain injury; disease modification in Alzheimer's and other neurodegenerative disease

Contraindications

Active or prior cancer

Strong hereditary cancer predisposition

Pregnancy or breastfeeding

Under 18

Proliferative or fibrotic disease

Key Interactions

c-Met inhibitors (crizotinib, cabozantinib, capmatinib)

Growth-factor or "BDNF-boosting" supplements

Other synaptogenic or growth-factor peptides

Risk & Side Effects

Low: Product contamination, mislabeling, and dosing errors

Speculative: Cancer promotion via HGF/c-Met pathway activation; unknown human safety profile; pathological angiogenesis and tissue fibrosis; overstimulation, headache, and neurological effects

Monitoring

Marker	Target	Why
Complete blood count (CBC)	Within standard reference range	Detects unexplained cytopenias or abnormalities
Comprehensive metabolic panel (CMP)	Fasting glucose 70–90 mg/dL; ALT/AST < 25 U/L	Screens organ function, including liver
hs-CRP	< 1.0 mg/L	Marker of systemic inflammation
Age-appropriate cancer screening	Per established screening guidelines	Central precaution given HGF/c-Met tumor concern

Cadence: Baseline, then repeat at 4–8 weeks and every 3–6 months; cancer screening on standard schedule

Qualitative Assessment

Subjective memory, recall, and learning ease
Mental clarity versus brain fog or overstimulation
Headache frequency or new neurological symptoms
Energy and mood stability
New or changing lumps, skin lesions, or unexplained symptoms

Dihexa for Cognitive Enhancement

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment